Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the ...

“Dosing adolescents is the first step in evaluating the safety and PK of nomlabofusp in pediatric patients with FA. We continue to enroll adolescents in our first cohort. This cohort will be ...

Larimar Therapeutics has initiated dosing for adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for nomlabofusp, a potential treatment for Friedreich’s ataxia.

Overall, 15.4% of children aged 0 to 35 months receive an invalid vaccine dose, receiving a vaccine earlier or later than recommended.

Innovations breaking barriers to children’s immunisation in Nigeria and Ethiopia win major funding from Save the Children ...

Aim: Little information is available regarding the influence of CYP3A5 genetic polymorphisms on tacrolimus dose requirement in pediatric liver transplantation. Patients & methods: We performed a ...

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced ...

ECT members have lingering questions about the Omega Lamplighters school and summer extension budgets being nearly as much as ...